PPBT — PURPLE BIOTECH LTD.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1614744 ·
Last close
$1.40
Market Cap
$1.31M
52W High
$4.48
52W Low
$1.33
ADV30
31,840
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -2,251,000 | -86,000 | 14,417,000 | 5,567,000 | 4,753,000 |
| Dec 2025 | 0 | — | -2,963,000 | -23,545,000 | 17,572,000 | 8,717,000 | 7,913,000 |
| Sep 2025 | 0 | — | -1,367,000 | -1,303,000 | 39,061,000 | 9,592,000 | 6,246,000 |
| Jun 2025 | 0 | — | -1,236,000 | -1,085,000 | 34,378,000 | 4,736,000 | 2,329,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-5,656,000
Investing CF
$632,000
Financing CF
$6,333,000
CapEx
—
Dividends Paid
$0
Buybacks
—
EPS Diluted TTM
$-546.00
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-171,079,000
Inventory
—
Receivables
$155,000
ST Investments
$857,000
EBIT TTM
$-26,429,000
Pretax Income TTM
$-26,492,000
Interest Exp TTM
$63,000
Analysts
1
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -6,976,000 | -26,386,000 | 17,572,000 | 7,913,000 | — | -5,656,000 |
| Dec 2024 | 0 | -10,803,000 | -7,240,000 | 37,038,000 | 4,127,000 | — | -14,367,000 |
| Dec 2023 | 0 | -22,271,000 | -19,880,000 | 44,302,000 | 10,005,000 | — | -19,925,000 |
| Dec 2022 | 0 | -22,603,000 | -21,668,000 | 54,622,000 | 7,524,000 | — | -16,735,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.88
Max Pain — expiry 2026-11-20 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $1.40 · call volume: 3 · put volume: 0
Expected Move to 2026-11-20:
±$1.53
(109.29%) —
implied range
$-0.13 –
$2.93
· ATM straddle on $2.50 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VBIO | Valion Bio, Inc. | $1.29M | $0.31 | — |
| ATXI | AVENUE THERAPEUTICS, INC. | $1.28M | $0.39 | — |
| HEPA | Hepion Pharmaceuticals, Inc. | $1.34M | $0.05 | — |
| CPMD | CANNAPHARMARX, INC. | $1.42M | $0.00 | — |
| BDRX | Biodexa Pharmaceuticals Plc | $1.19M | $1.32 | — |
News headlines (Yahoo Finance, 1h cache)
Purple Biotech Presents New IM1240 Preclinical Data Showing Anti-Tumor Activity and Broad Therapeutic Window (PPBT)
2026-06-11 14:38 · Yahoo
Purple Biotech Presents New Preclinical Data at EACR 2026 Highlighting IM1240's Anti-Tumor Activity, Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window
2026-06-11 11:00 · Yahoo
Purple Biotech Reports First Quarter 2026 Financial Results and Business Highlights
2026-05-15 11:00 · Yahoo
Purple Biotech Announces New Data from CAPTN-3 Platform Tri-specific IM1240
2026-04-27 11:00 · Yahoo
Purple Biotech Establishes Scientific Advisory Board to Support Development of CAPTN-3 Tri-Specific Antibody Platform
2026-04-23 11:00 · Yahoo
Purple Biotech Announces AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform
2026-03-25 12:00 · Yahoo
Purple Biotech Regains Compliance with Nasdaq
2026-03-17 11:00 · Yahoo
Purple Biotech Announces CEO Transition
2026-03-13 12:04 · Yahoo
Purple Biotech Reports Fourth Quarter and Full Year 2025 Financial Results
2026-03-13 12:00 · Yahoo
Purple Biotech Announces Plan to Implement ADS Ratio Change
2026-02-25 21:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.